Vaccine maker Pfizer has reported record revenues for 2022, with its COVID-19 products accounting for a large chunk of the sales even as the company is facing backlash for claiming to “mutate” viruses, and a growing number of doctors are turning away from boosters.
Full-year revenues for 2022 came in at $100.3 billion, which is an “all-time high” for the multinational corporation, according to the earnings release by Pfizer on Jan. 31. This is the first time the company has seen annual sales in excess of $100 billion, with revenues reflecting 30 percent operational growth. Excluding contributions from COVID-19 products, Comirnaty vaccine and Paxlovid antiviral, revenues only grew by 2 percent operationally. The two products combined generated over $56 billion in sales for the company.
The year “2022 was a record-breaking year for Pfizer, not only in terms of revenue and earnings per share, which were the highest in our long history,” said Dr. Albert Bourla, chairman and CEO of Pfizer.
“As we turn to 2023, we expect to once again set records, with potentially the largest number of new product and indication launches that we’ve ever had in such a short period of time.”
Sales of Comirnaty and Paxlovid are expected to hit their lowest levels in 2023 before getting back to growth next year “due to significant government supply on hand” at the beginning of this year, the company said.
Pfizer calculates Comirnaty sales to decline by 64 percent, to $13.5 billion this year, and Paxlovid sales to drop 58 percent, to $8 billion.
Hellbound and Down 